Personal Data of Study Subjects Sample Clauses

Personal Data of Study Subjects. Pfizer shall be an independent Controller with respect to its Processing of Personal Data contained in the Study data that is reported by Health Services Provider to Pfizer or CRO. Health Services Provider shall continue to be an independent Controller of Personal Data Processed by Health Services Provider with respect to the treatment of the Study subject pursuant to medical standard of care and applicable legal obligations. Health Services Provider agrees to obtain from each Study subject, prior to that individual’s participation in the Study, a signed informed consent, approved in writing by Pfizer or CRO and by any applicable ethics committee, and which shall include the necessary content to allow for the Processing of the Study subject’s Personal Data for the purposes described in the Study protocol and the Agreement. 2. Osobní údaje subjektů hodnocení. Společnost Pfizer bude nezávislým Správcem, co se týká Zpracovávání Osobních údajů obsažených v údajích Studie, které předává Poskytovatel zdravotních služeb společnosti Pfizer nebo CRO. Poskytovatel zdravotních služeb bude nadále nezávislým Správcem Osobních údajů Zpracovávaných Zdravotnickým zařízením s ohledem na léčbu subjektů hodnocení podle standardů lékařské péče a příslušných právních povinností. Poskytovatel zdravotních služeb souhlasí s tím, že před individuální účastí ve Studii získá od každého subjektu hodnocení podepsaný informovaný souhlas, písemně schválený společností Pfizer nebo CRO a příslušnou etickou komisí, který bude zahrnovat nezbytný obsah dovolující Zpracovávání Osobních údajů subjektu hodnocení pro účely popsané v protokolu Studie a Smlouvě.
Sample 1See All (6)
AutoNDA by SimpleDocs
Personal Data of Study Subjects. Pfizer will be an independent Controller with respect to its Processing of Personal Data contained in the Study Data and Biological Samples that are reported by Institution or Principal Investigator to Pfizer or otherwise created by Pfizer. Institution or Principal Investigator is the Controller of Personal Data Processed with respect to the medical treatment of the Study Subject.
Sample 1Sample 2
Personal Data of Study Subjects. Parties acknowledge that Pfizer shall act as an independent Controller with respect to its Processing of coded Personal Data of Study Subjects obtained in accordance with Informed consent form, and with respect to Personal Data of Investigator and Institution's employees obtained in accordance with Agreement that is reported by Institution to Pfizer or CRO. Institution shall act as an independent Controller of any medical records obtained by Investigator from Study Subjects and any other Personal Data gathered or generated by Investigator in the course of the Study for the purposes of conducting his independent medical judgment in accordance with the Protocol and with respect to the treatment of the Study subject pursuant to medical standard of care and applicable legal obligations. The Parties and Pfizer acknowledge that the Investigator shall obtain from each Study subject, prior to that individual’s participation in the Study, a signed informed consent, approved in writing by Pfizer or CRO and by any applicable ethics committee, and which shall include the necessary content to allow for the Processing of the Study subject’s Personal Data for the purposes described in the Study protocol and the Agreement. 2. Osobní údaje subjektů hodnocení. Strany berou na vědomí, že Pfizer jedná jako Správce údajů ve vztahu ke kódovaným Osobním údajům subjektů Studie získaným v souladu s Formulářem informovaného souhlasu a Osobním údajům Zkoušejícího a zaměstnanců Instituce získaným dle Smlouvy. Instituce jedná jako Správce údajů ve vztahu k jakýmkoli zdravotním záznamům, které Zkoušející získal od subjektů Studie, a jakýmkoli dalším osobním údajům, které Zkoušející shromáždil nebo vygeneroval v průběhu Studie pro účely provádění jeho nezávislého lékařského úsudku v souladu s Protokolem a s ohledem na léčbu subjektů hodnocení podle standardů lékařské péče a příslušných právních povinností. Smluvní strany a Pfizer berou na vědomí, že zkoušející před individuální účastí ve Studii získá od každého subjektu hodnocení podepsaný informovaný souhlas, písemně schválený společností Pfizer nebo CRO a příslušnou etickou komisí, který bude zahrnovat nezbytný obsah dovolující Zpracovávání Osobních údajů subjektu hodnocení pro účely popsané v protokolu Studie a Smlouvě.
Sample 1
Personal Data of Study Subjects. 6.2.1 Sponsor, as Controller of the Personal Data of Study Subjects processed for the purpose of the Study (“Study-related Personal Data of Study Subjects”), delegated processing of Study- related Personal Data of Study subjects, including, without limitation, Study-related data on medical condition of Study Subjects, to Institution. The scope of such processing and of the data processed is defined by the case report forms (CRFs) used in this Study and by the Protocol.
Sample 1
Personal Data of Study Subjects. XXX will be an independent Controller with respect to its Processing of Personal Data contained in the Study Data and Biological Samples that are reported by Institution or Principal Investigator to XXX or otherwise created by XXX. Institution or Principal Investigator is the Controller of Personal Data Processed by Institution with respect to the medical treatment of the StudySubject.
Sample 1

Related to Personal Data of Study Subjects

  • Processing Personal Data 40.1. The Company is the data controller in the relevant jurisdiction. You hereby acknowledge and agree to the collection and processing of personal data provided by you in connection with the opening of a trading account for the purpose of performing our obligations under these Terms and Conditions and for administering the relationship between you and us.

  • Personal Data Processing 2.1 The Processor shall process Personal Data only on the basis of corresponding recorded orders from the Controller.

  • Personal Data Registry Operator shall (i) notify each ICANN-­‐accredited registrar that is a party to the registry-­‐registrar agreement for the TLD of the purposes for which data about any identified or identifiable natural person (“Personal Data”) submitted to Registry Operator by such registrar is collected and used under this Agreement or otherwise and the intended recipients (or categories of recipients) of such Personal Data, and (ii) require such registrar to obtain the consent of each registrant in the TLD for such collection and use of Personal Data. Registry Operator shall take reasonable steps to protect Personal Data collected from such registrar from loss, misuse, unauthorized disclosure, alteration or destruction. Registry Operator shall not use or authorize the use of Personal Data in a way that is incompatible with the notice provided to registrars.

  • Shared Personal Data This clause sets out the framework for the sharing of personal data between the parties as data controllers. Each party acknowledges that one party (the Data Discloser) will regularly disclose to the other party (the Data Recipient) Shared Personal Data collected by the Data Discloser for the Agreed Purposes.

  • Processing of Personal Data (a) SORACOM collects and processes personal data about the Subscriber, including name, e-mail, IP-address as well as data on data uses and billing data in order to provide SORACOM’s service and other purposes such as billing.

  • Transfer of Personal Data The Participant authorizes, agrees and unambiguously consents to the transmission by the Company (or any Subsidiary) of any personal data information related to the Option awarded under this Agreement for legitimate business purposes (including, without limitation, the administration of the Plan). This authorization and consent is freely given by the Participant.

  • Deletion and Return of Personal Data (1) Copies or duplicates of the data shall never be created without the knowledge of the Client, with the exception of back-up copies as far as they are necessary to ensure orderly data processing, as well as data required to meet regulatory requirements to retain data.

  • Handling Sensitive Personal Information and Breach Notification A. As part of its contract with HHSC Contractor may receive or create sensitive personal information, as section 521.002 of the Business and Commerce Code defines that phrase. Contractor must use appropriate safeguards to protect this sensitive personal information. These safeguards must include maintaining the sensitive personal information in a form that is unusable, unreadable, or indecipherable to unauthorized persons. Contractor may consult the “Guidance to Render Unsecured Protected Health Information Unusable, Unreadable, or Indecipherable to Unauthorized Individuals” issued by the U.S. Department of Health and Human Services to determine ways to meet this standard.

  • Transfer of Personal Information Supplier warrants to DXC that Personal Information provided to Supplier or obtained by Supplier under this Agreement on behalf of DXC (including any SOW) shall not be transferred across national boundaries unless authorized by law or specified within this Agreement or the applicable SOW as authorized for transfer across national boundaries. Supplier agrees that any such transfer will only be made in compliance with applicable Data Privacy Laws. If there is a conflict between this Section ‘Data Protection and Privacy’ and the other provisions of this Agreement, the requirements of this Section shall take precedence.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

Time is Money Join Law Insider Premium to draft better contracts faster.